00:17 , Sep 15, 2018 |  BioCentury  |  Finance

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
19:16 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Hua raises $110.5M in HK IPO, trades flat on first day

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Sept. 14. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of...
13:39 , Sep 14, 2018 |  BC Extra  |  Financial News

Hua trades flat in Hong Kong debut

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Friday. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8...
17:43 , Sep 13, 2018 |  BC Extra  |  Financial News

Hua raises $110M in Hong Kong IPO

Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
15:31 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Hua Medicine planning Hong Kong IPO

Diabetes company Hua Medicine Ltd. (Shanghai, China) filed for an IPO on the Hong Kong stock exchange underwritten by Goldman Sachs and CLSA Capital Markets. Hua is the second biotech company to file for a Hong...
15:20 , Jun 6, 2018 |  BC Extra  |  Financial News

Hua Medicine planning Hong Kong IPO

Diabetes company Hua Medicine Ltd. (Shanghai, China) filed for an IPO on the Hong Kong stock exchange underwritten by Goldman Sachs and CLSA Capital Markets. Hua is the second biotech company to file for a Hong...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
17:20 , May 11, 2018 |  BC Week In Review  |  Clinical News

Hua's dorzagliatin reduces HbA1c in Phase II for Type II diabetes

Hua Medicine Ltd. (Shanghai, China) reported data from a double-blind, Chinese Phase II trial in 258 Type II diabetics showing that twice-daily 50 and 75 mg doses of oral dorzagliatin (sinogliatin, HMS5552, RO5305552) both significantly...
13:36 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s disease candidate missed the co-primary endpoints in Part A of the Phase III STEADFAST trials to treat mild AD. STEADFAST...